Pharma IQ’s Clinical Trial Supply survey delved into ten key areas such as these to find out more about the main challenges you face. Don't miss a chance to learn what the consensus of your industry is in these survey findings. Download the full results below...some were surprising, but you spoke and we listened!
1. Pharma IQ’s Clinical Trial Supply Europe Survey Results
www.clinicalsupplyeurope.com
This survey was conducted with key members of the Clinical Trial Supply
area to gain an insight into how professionals are investing in Clinical Trial
Supply, the regions they are operating in and their top priorities for 2010-11.
2. How many years have you been working in the
Clinical T rial Supplies area?
19%
33%24%
24%
1-5
6-10
11 -15
16+
www.clinicalsupplyeurope.com
3. What is your number 1 priority area for 2011?
5%
63%
9%
18%
5%
Cost cutting
Overage cuts
Supporting numerous new
trials
Supporting current trials
Working specifically for trials
in emerging markets
Other (providing excellent
customer service)
www.clinicalsupplyeurope.com
4. Which areas are you looking to invest in for 2011?
24% 24%
19%
43%
5%
33%
14%
0%
10%
20%
30%
40%
50%
Packagingandlabelling
technologies/outsourcing
Supplynetworkfornew
clinicaltrial/s
Comparatortrials
Coolchaintechnologies
Greenersupplychain
Supplychainsin
emergingmarkets
Other(pleasespecify)
Other areas include investing in Asia, forecasting systems and all of the above.
N.B. Participants chose multiple options
www.clinicalsupplyeurope.com
5. Approximately how many active trials does your
company run a year?
10%
10%
24%
56%
1-10
11-20
21-30
31-40
41-50
50+
www.clinicalsupplyeurope.com
6. Of these, how many of these will be in BRIC countries in 2011?
19%
38%
14%
29%
5 or less
6-10
11-15
16+
www.clinicalsupplyeurope.com
7. Which areas are proving to be the most difficult to ship to?
52%
5%
29%
14%
10%
0%
10%
20%
30%
40%
50%
60%
Russia and the
Ukraine
India China Latin America Other (please
specify)
www.clinicalsupplyeurope.com
8. Which aspects of the Clinical T rial Supply function in your
company is outsourced?
29%
43%
24%
48%
29%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
Manufacture Packaging and
labelling
Logistics Distribution Other (please
specify)
Other: Depot services, part of co-ordination, IVRS and all of the above
N.B. Participants chose multiple options
www.clinicalsupplyeurope.com
9. How many 3rd party partners do you work with in the CT S space?
47%
29%
5%
19%
5 or less
6-10
11-15
16+
www.clinicalsupplyeurope.com
10. What is your primary motivation for outsourcing?
14%
53%
33% Cost cutting
Lack of internal
experience/capabilities
Other (please specify)
Other: Lack of local presence in other continents, lack of
resource flexibility and under developed IVRS technology.
www.clinicalsupplyeurope.com
11. www.clinicalsupplyeurope.com
Clinical Trial Supply Europe
Dates: 26 - 28 January, 2011
Venue: World Trade Centre, Rotterdam, The Netherlands
Innovative techniques for effective clinical supply planning, packaging and distribution to cut costs and
speed time to market
In response to industry demand, Pharma IQ’s Clinical Trial Supply Europe conference will bring together senior
industry experts from across the globe to discuss innovative approaches to planning, packaging, distribution,
comparator sourcing and much more in three days of interactive presentations and discussions.
The 30 Clinical Trial experts will be sharing their expertise on:
•Maintaining compliance with the evolving GxP regulatory landscape
•Ensuring product viability of temperature controlled clinical materials
•Guaranteeing uninterrupted supply in emerging markets such as Eastern Europe and Latin America
PLUS! Don't miss:
1. 8+ hours of dedicated networking including an Evening Drinks Reception and Gala Dinner
2. Two tailored streams
3. Exclusive to Pharma IQ: Interactive Crisis Management Session
For more information or to register:
Tel: +44 207 368 9300
Email: enquire@iqpc.co.uk
Visit: http://www.clinicalsupplyeurope.com
